A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine in 13-valent Pneumococcal Vaccine, Immunization and Safety, sponsored by Pfizer. Completed at 25 sites in France. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-08.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during infancy in Study 6096A1-008-EU (NCT00366678). In this study, participants will receive an additional dose of 13-valent pneumococcal conjugate vaccine. The purpose of this study is to evaluate persistence, if any, of the antibody response by measuring any remaining pneumococcal antibodies since the previous study. This study will also evaluate the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine when administered at least 24 months after the last dose of pneumococcal conjugate vaccine.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose (0.5 mL), IM of 13vPnC vaccine.
Biological: 13-valent pneumococcal conjugate vaccine
All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine
Antibody GMC as measured by microgram/millilitre (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Time frame: One month after vaccination
Percentage of Participants With Prespecified Local Reactions
Local reactions (redness, swelling and pain) were reported using electronic diary. Redness and swelling were recorded in caliper units (range 1 to 14+), each caliper unit represented 0.5 cm. Categorized as any, absent (no redness or swelling present; 0 caliper units), mild (0.5 to 2.0 cm; 1 to 4 caliper units); moderate (2.5 to 7.0 cm; 5 to 14 caliper units); or severe (\>7.0 cm; \>14 caliper units). Pain was categorized as any, mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity. Participants may be reported in more than 1 category.
Time frame: Seven days after vaccination
Percentage of Participants With Prespecified Systemic Events
Systemic events (any fever \>= 38 degree celsius \[C\], vomiting, diarrhea, and fatigue) were reported using electronic diary. Fever categorized as \>=38 to \<=39 degree C; \>39 to \<=40 degree C; \>40 degree C. Vomiting: mild (1-2 times/day ); moderate (\>2 times/day); severe (requires intravenous hydration). Diarrhea: mild (2-3 loose stools/day); moderate (4-5 stools/day); severe (\>=6 loose stools/day). Fatigue: mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity). Participants may be reported in more than 1 category.
Time frame: Seven days after vaccination
Serotype-specific Pneumococcal IgG GMC Prior to Single Dose of 13vPnC Vaccine
IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG enzymelinked immunosorbent assay (ELISA). CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: Up to 7 days before vaccination
Serotype-specific Pneumococcal IgG GMC at 4 to 7 Days After the Single Dose of 13vPnC Vaccine
IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG ELISA. CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: Four to seven days after vaccination
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Prior to Single Dose of 13vPnC Vaccine
Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: Up to 7 days before vaccination
Serotype-specific OPA GMTs 1 Month After Single Dose of 13vPnC Vaccine
Serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: One month after vaccination
Percentage of Participants With at Least 1/8 Serotype-specific OPA GMTs After Single Dose of 13vPnC Vaccine
Percentage of participants with at least 1/8 serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) determined in the blood samples of all participants.
Time frame: One month after vaccination
Percentage of Participants With at Least 1/2048 OPA GMTs for Serotype 7F After Single Dose of 13vPnC Vaccine
Percentage of participants with at least 1/2048 serotype-specific pneumococcal OPA GMTs for serotype 7F determined in the blood samples of all participants.
Time frame: One month after vaccination
| Milestone | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| Started | 130 | 65 | 67 |
| Completed | 129 | 64 | 67 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
Antibody GMC as measured by microgram/millilitre (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
| mcg/mL | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| 4 | 10.34 (8.94 to 11.97) | 12.79 (10.00 to 16.35) | 8.98 (6.98 to 11.56) |
| 6B | 31.62 (27.02 to 37.01) | 51.07 (38.65 to 67.49) | 35.38 (27.25 to 45.93) |
| 9V | 6.76 (5.90 to 7.73) | 6.50 (5.31 to 7.95) | 6.19 (5.04 to 7.61) |
| 14 | 21.55 (18.41 to 25.24) | 21.15 (16.89 to 26.48) | 20.73 (16.45 to 26.12) |
| 18C | 4.56 (3.93 to 5.29) | 6.12 (4.89 to 7.65) | 5.35 (4.27 to 6.71) |
| 19F | 16.59 (13.57 to 20.28) | 12.07 (9.35 to 15.59) | 15.09 (11.17 to 20.39) |
| 23F | 8.68 (7.50 to 10.03) | 10.87 (8.30 to 14.22) | 9.10 (7.34 to 11.28) |
| 1 | 10.72 (9.17 to 12.52) | 2.96 (2.45 to 3.59) | 20.69 (16.14 to 26.53) |
| 3 | 1.81 (1.46 to 2.23) | 1.60 (1.19 to 2.17) | 2.07 (1.66 to 2.59) |
| 5 | 10.00 (8.63 to 11.58) | 2.86 (2.37 to 3.46) | 19.20 (14.93 to 24.70) |
| 6A | 23.09 (19.50 to 27.33) | 14.38 (10.53 to 19.64) | 18.60 (13.87 to 24.93) |
| 7F | 8.23 (7.11 to 9.52) | 5.04 (4.16 to 6.11) | 8.02 (6.66 to 9.67) |
| 19A | 17.10 (14.54 to 20.11) | 8.58 (6.70 to 10.99) | 16.46 (13.42 to 20.19) |
Local reactions (redness, swelling and pain) were reported using electronic diary. Redness and swelling were recorded in caliper units (range 1 to 14+), each caliper unit represented 0.5 cm. Categorized as any, absent (no redness or swelling present; 0 caliper units), mild (0.5 to 2.0 cm; 1 to 4 caliper units); moderate (2.5 to 7.0 cm; 5 to 14 caliper units); or severe (\>7.0 cm; \>14 caliper units). Pain was categorized as any, mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity. Participants may be reported in more than 1 category.
| Percentage of Participants | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| Pain: Any (n= 112, 52, 53) | 55.4 | 55.8 | 64.2 |
| Pain: Mild (n= 109, 51, 51) | 50.5 | 49.0 | 56.9 |
| Pain: Moderate (n= 95, 47, 48) | 17.9 | 25.5 | 20.8 |
| Pain: Severe (n= 90, 43, 45) | 1.1 | 2.3 | 2.2 |
| Swelling: Any (101, 48, 47) | 39.6 | 41.7 | 27.7 |
| Swelling: Mild (n= 96, 48, 47) | 28.1 | 35.4 | 23.4 |
| Swelling: Moderate (n= 97, 44, 46) | 24.7 | 20.5 | 10.9 |
| Swelling: Severe (n= 90, 43, 45) | 0.0 | 2.3 | 0.0 |
| Redness: Any (n= 105, 50, 50) | 48.6 | 54.0 | 46.0 |
| Redness: Mild (n= 101, 49, 48) | 38.6 | 40.8 | 37.5 |
| Redness: Moderate (n= 95, 45, 47) | 22.1 | 31.1 | 17.0 |
| Redness: Severe (n= 90, 43, 45) | 0.0 | 2.3 | 0.0 |
Systemic events (any fever \>= 38 degree celsius \[C\], vomiting, diarrhea, and fatigue) were reported using electronic diary. Fever categorized as \>=38 to \<=39 degree C; \>39 to \<=40 degree C; \>40 degree C. Vomiting: mild (1-2 times/day ); moderate (\>2 times/day); severe (requires intravenous hydration). Diarrhea: mild (2-3 loose stools/day); moderate (4-5 stools/day); severe (\>=6 loose stools/day). Fatigue: mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity). Participants may be reported in more than 1 category.
| Percentage of Participants | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| Fever >=38 to <=39 degree C (n= 93, 49, 46) | 15.1 | 28.6 | 19.6 |
| Fever >39 to <=40 degree C (n= 92, 43, 46) | 2.2 | 4.7 | 2.2 |
| Fever >40 degree C (n= 90, 43, 45) | 0.0 | 0.0 | 2.2 |
| Vomiting: Any (n= 91, 44, 45) | 3.3 | 9.1 | 6.7 |
| Vomiting: Mild (n= 91, 44, 45) | 3.3 | 9.1 | 6.7 |
| Vomiting: Moderate (n= 90, 43, 45) | 0.0 | 0.0 | 0.0 |
| Vomiting: Severe (n= 90, 43, 45) | 0.0 | 0.0 | 0.0 |
| Diarrhea: Any (n= 90, 45, 47) | 8.9 | 17.8 | 8.5 |
| Diarrhea: Mild (n= 90, 45, 47) | 8.9 | 17.8 | 8.5 |
| Diarrhea: Moderate (n= 90, 43, 45) | 1.1 | 0.0 | 0.0 |
| Diarrhea: Severe (n= 90, 43, 45) | 0.0 | 0.0 | 0.0 |
| Fatigue: Any (n= 103, 54, 48) | 40.8 | 51.9 | 31.3 |
| Fatigue: Mild (n= 100, 49, 48) | 34.0 | 34.7 | 20.8 |
| Fatigue: Moderate (n= 96, 49, 46) | 16.7 | 30.6 | 15.2 |
| Fatigue: Severe (n= 92, 43, 45) | 3.3 | 2.3 | 2.2 |
IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG enzymelinked immunosorbent assay (ELISA). CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| 4 | 0.17 (0.15 to 0.21) | 0.23 (0.18 to 0.30) | 0.18 (0.15 to 0.22) |
| 6B | 2.86 (2.35 to 3.48) | 4.10 (2.96 to 5.68) | 3.21 (2.37 to 4.36) |
| 9V | 0.72 (0.60 to 0.85) | 0.92 (0.72 to 1.17) | 0.71 (0.58 to 0.87) |
| 14 | 0.77 (0.61 to 0.98) | 0.74 (0.52 to 1.06) | 0.59 (0.42 to 0.83) |
| 18C | 0.21 (0.17 to 0.25) | 0.36 (0.28 to 0.47) | 0.23 (0.18 to 0.28) |
| 19F | 2.22 (1.67 to 2.95) | 2.11 (1.43 to 3.11) | 1.44 (1.04 to 2.02) |
| 23F | 1.26 (1.00 to 1.58) | 1.56 (1.19 to 2.05) | 1.18 (0.92 to 1.52) |
| 1 | 0.35 (0.29 to 0.43) | 0.14 (0.09 to 0.20) | 0.28 (0.23 to 0.34) |
| 3 | 0.50 (0.35 to 0.71) | 0.47 (0.29 to 0.75) | 0.42 (0.30 to 0.58) |
| 5 | 1.28 (1.07 to 1.53) | 1.12 (0.89 to 1.41) | 1.41 (1.19 to 1.67) |
| 6A | 4.05 (3.25 to 5.04) | 1.89 (1.50 to 2.38) | 2.47 (1.91 to 3.21) |
| 7F | 0.65 (0.55 to 0.78) | 0.21 (0.15 to 0.30) | 0.77 (0.62 to 0.96) |
| 19A | 6.16 (4.88 to 7.79) | 3.38 (2.60 to 4.41) | 4.63 (3.43 to 6.26) |
IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG ELISA. CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| 4 | 2.96 (1.67 to 5.24) | 4.66 (2.01 to 10.82) | 3.85 (1.70 to 8.74) |
| 6B | 17.78 (12.50 to 25.30) | 19.15 (8.84 to 41.48) | 16.26 (8.10 to 32.66) |
| 9V | 3.49 (2.39 to 5.09) | 3.15 (1.75 to 5.66) | 3.20 (1.86 to 5.50) |
| 14 | 5.55 (3.32 to 9.30) | 5.67 (2.29 to 13.99) | 4.52 (2.14 to 9.52) |
| 18C | 2.31 (1.36 to 3.91) | 3.34 (1.66 to 6.72) | 2.51 (1.33 to 4.73) |
| 19F | 11.70 (7.21 to 19.00) | 6.88 (2.98 to 15.86) | 8.51 (4.38 to 16.55) |
| 23F | 5.24 (3.49 to 7.87) | 5.82 (2.97 to 11.40) | 6.28 (3.50 to 11.26) |
| 1 | 4.24 (2.48 to 7.26) | 0.56 (0.27 to 1.18) | 8.00 (3.51 to 18.23) |
| 3 | 1.24 (0.79 to 1.95) | 1.12 (0.56 to 2.25) | 1.24 (0.90 to 1.72) |
| 5 | 6.00 (4.16 to 8.66) | 1.43 (0.99 to 2.06) | 9.81 (5.29 to 18.19) |
| 6A | 13.86 (9.69 to 19.83) | 4.46 (2.18 to 9.12) | 7.37 (3.95 to 13.78) |
| 7F | 3.55 (2.35 to 5.36) | 1.23 (0.69 to 2.21) | 3.08 (1.72 to 5.51) |
| 19A | 13.07 (9.63 to 17.74) | 5.09 (3.17 to 8.19) | 10.50 (7.12 to 15.50) |
Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| Geometric mean titers | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| 4 (n= 40, 14, 19) | 8 (4.4 to 13.1) | 46 (7.8 to 268.5) | 45 (10.6 to 190.6) |
| 6B (n= 38, 16, 21) | 245 (92.6 to 646.9) | 247 (49.1 to 1241.8) | 332 (84.4 to 1304.3) |
| 9V (n= 40, 18, 21) | 43 (16.3 to 111.9) | 36 (8.6 to 149.1) | 52 (14.6 to 187.8) |
| 14 (n= 39, 16, 20) | 98 (39.7 to 242.9) | 40 (9.2 to 174.2) | 49 (14.4 to 163.9) |
| 18C (n= 42, 17, 19) | 14 (6.9 to 27.7) | 76 (15.7 to 363.0) | 28 (7.2 to 109.7) |
| 19F (n= 43, 17, 21) | 48 (20.8 to 112.5) | 49 (13.0 to 182.6) | 40 (14.0 to 112.5) |
| 23F (n= 43, 16, 21) | 52 (22.5 to 120.3) | 61 (13.1 to 284.3) | 178 (54.6 to 578.7) |
| 1 (n= 44, 18, 22) | 6 (4.5 to 7.5) | 5 (3.4 to 6.5) | 10 (6.9 to 15.0) |
| 3 (n= 42, 17, 21) | 20 (11.8 to 34.6) | 10 (4.4 to 22.2) | 18 (12.1 to 28.0) |
| 5 (n= 44, 18, 22) | 4 (NA to NA) | 4 (NA to NA) | 4 (3.6 to 5.6) |
| 6A (n= 44, 16, 21) | 170 (72.8 to 395.5) | 10 (3.4 to 31.4) | 75 (22.3 to 253.9) |
| 7F (n= 39, 16, 21) | 60 (22.5 to 157.8) | 47 (10.0 to 225.2) | 389 (112.0 to 1351.1) |
| 19A (n= 41, 18, 20) | 118 (58.2 to 239.7) | 25 (7.4 to 82.0) | 124 (46.4 to 330.2) |
Serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| Geometric mean titers | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| 4 (n= 117, 53, 55) | 5465 (4698.9 to 6356.4) | 5208 (4301.7 to 6304.2) | 5487 (4236.9 to 7106.4) |
| 6B (n= 117, 57, 56) | 6684 (5638.4 to 7924.4) | 10042 (7697.5 to 13101.6) | 8983 (7006.9 to 11516.8) |
| 9V (n= 116, 54, 55) | 5120 (4456.1 to 5882.6) | 4052 (3291.0 to 4989.7) | 5221 (4110.4 to 6630.7) |
| 14 (n= 115, 54, 55) | 2780 (2374.7 to 3254.6) | 3079 (2450.6 to 3869.4) | 2979 (2232.9 to 3973.4) |
| 18C (n= 117, 54, 57) | 7711 (6589.6 to 9023.3) | 7091 (5655.9 to 8889.9) | 8431 (6740.3 to 10545.7) |
| 19F (n= 118, 57, 57) | 1319 (1030.5 to 1689.5) | 1721 (1316.8 to 2250.3) | 1914 (1350.6 to 2712.5) |
| 23F (n= 118, 53, 56) | 2427 (2063.6 to 2855.0) | 2411 (1792.5 to 3242.4) | 2673 (2091.2 to 3417.3) |
| 1 (n= 119, 56, 57) | 613 (525.2 to 715.7) | 197 (161.4 to 239.4) | 1212 (968.0 to 1516.9) |
| 3 (n= 118, 56, 58) | 244 (214.7 to 276.4) | 173 (139.5 to 214.5) | 291 (239.4 to 353.7) |
| 5 (n= 118, 55, 54) | 455 (358.7 to 537.9) | 390 (281.2 to 541.8) | 728 (545.0 to 972.2) |
| 6A (n= 117, 55, 55) | 5580 (4593.6 to 6777.0) | 5596 (4276.6 to 7321.2) | 5982 (4450.7 to 8041.1) |
| 7F (n= 118, 56, 54) | 4323 (3794.4 to 4925.1) | 8048 (6500.9 to 9962.2) | 4056 (3092.2 to 5321.2) |
| 19A (n= 116, 53, 54) | 1212 (1048.1 to 1400.7) | 1249 (956.5 to 1632.3) | 1568 (1249.7 to 1966.1) |
Percentage of participants with at least 1/8 serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) determined in the blood samples of all participants.
No measurements were reported for this outcome.
Percentage of participants with at least 1/2048 serotype-specific pneumococcal OPA GMTs for serotype 7F determined in the blood samples of all participants.
No measurements were reported for this outcome.
Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using mcOPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43; Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; Pn23F, 13. LOD established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.
| Percentage of Participants | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| 4 (n= 117, 53, 55) | 100.0 (96.9 to 100.0) | 100.0 (93.3 to 100.0) | 100.0 (93.5 to 100.0) |
| 6B (n= 117, 57, 56) | 100.0 (96.9 to 100.0) | 100.0 (93.7 to 100.0) | 100.0 (93.6 to 100.0) |
| 9V (n= 116, 54, 55) | 100.0 (96.9 to 100.0) | 100.0 (93.4 to 100.0) | 100.0 (93.5 to 100.0) |
| 14 (n= 115, 54, 55) | 100.0 (96.8 to 100.0) | 100.0 (93.4 to 100.0) | 100.0 (93.5 to 100.0) |
| 18C (n= 117, 54, 57) | 100.0 (96.9 to 100.0) | 100.0 (93.4 to 100.0) | 100.0 (93.7 to 100.0) |
| 19F (n= 118, 57, 57) | 98.3 (94.0 to 99.8) | 100.0 (93.7 to 100.0) | 98.2 (90.6 to 100.0) |
| 23F (n= 118, 53, 56) | 100.0 (96.9 to 100.0) | 100.0 (93.3 to 100.0) | 100.0 (93.6 to 100.0) |
| 1 (n= 119, 56, 57) | 100.0 (96.9 to 100.0) | 100.0 (93.6 to 100.0) | 100.0 (93.7 to 100.0) |
| 3 (n= 118, 56, 58) | 100.0 (96.9 to 100.0) | 98.2 (90.4 to 100.0) | 100.0 (93.8 to 100.0) |
| 5 (n= 118, 55, 54) | 99.2 (95.4 to 100.0) | 96.4 (87.5 to 99.6) | 100.0 (93.4 to 100.0) |
| 6A (n= 117, 55, 55) | 100.0 (96.9 to 100.0) | 100.0 (93.5 to 100.0) | 100.0 (93.5 to 100.0) |
| 7F (n= 118, 56, 54) | 100.0 (96.9 to 100.0) | 100.0 (93.6 to 100.0) | 100.0 (93.4 to 100.0) |
| 19A (n= 116, 53, 54) | 100.0 (96.9 to 100.0) | 100.0 (93.3 to 100.0) | 100.0 (93.4 to 100.0) |
Collected over AEs/SAEs: recorded from signing of informed consent form to completion of study (28-42 days post 13vPnC). Participants recorded prespecified AEs in electronic diary:local reactions; systemic events; use of antipyretic medication (Day 1-Day 7 post 13vPnC).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC/13vPnC/13vPnC | — | 0/130 (0%) | 82/130 (63.1%) |
| 7vPnC/7vPnC/13vPnC | — | 0/64 (0%) | 36/64 (56.3%) |
| 7vPnC/13vPnC/13vPnC | — | 0/64 (0%) | 39/64 (60.9%) |
| Event | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC |
|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | 62/112 | 29/52 | 34/53 |
| Pain (Mild)Skin and subcutaneous tissue disorders | 55/109 | 25/51 | 29/51 |
| Redness (Any)Skin and subcutaneous tissue disorders | 51/105 | 27/50 | 23/50 |
| Fatigue (Any)General disorders | 42/103 | 28/54 | 15/48 |
| Swelling (Any)Skin and subcutaneous tissue disorders | 40/101 | 20/48 | 13/47 |
| Redness (Mild)Skin and subcutaneous tissue disorders | 39/101 | 20/49 | 18/48 |
| Swelling (Mild)Skin and subcutaneous tissue disorders | 27/96 | 17/48 | 11/47 |
| Fatigue (Mild)General disorders | 34/100 | 17/49 | 10/48 |
| Redness (Moderate)Skin and subcutaneous tissue disorders | 21/95 | 14/45 | 8/47 |
| Fatigue (Moderate)General disorders | 16/96 | 15/49 | 7/46 |
| Age Continuous(Years) | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC | Total |
|---|---|---|---|---|
| Mean | 3.4 ± 0.25 | 3.4 ± 0.24 | 3.5 ± 0.25 | 3.4 ± 0.25 |
| Sex: Female, Male(Participants) | 13vPnC/13vPnC/13vPnC | 7vPnC/7vPnC/13vPnC | 7vPnC/13vPnC/13vPnC | Total |
|---|---|---|---|---|
| Female | 70 | 29 | 40 | 139 |
| Male | 60 | 36 | 27 | 123 |
The record gives a start of Apr 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine